Fast, portable tests come online to curb coronavirus pandemic
- C. Sheridan
- Materials ScienceNature Biotechnology
- 23 March 2020
Testing kits delivered by courier and digital tools combine to battle the COVID-19 outbreak to find out which kits are most effective in protecting against infection.
Gene therapy finds its niche
- C. Sheridan
- MedicineNature Biotechnology
- 7 February 2011
Gene therapy is finally poised to make a contribution to the treatment of debilitating, highly penetrant genetic diseases that have proved intractable to other regimens.
Coronavirus and the race to distribute reliable diagnostics
- C. Sheridan
- MedicineNature Biotechnology
- 19 February 2020
International teams worked at speed to make tests for the virus available in record time, with results shown in less than a minute.
First Axl inhibitor enters clinical trials
- C. Sheridan
- BiologyNature Biotechnology
- 10 September 2013
It is shown that people who self-identified as seekers of happiness through living a life of purpose have a gene expression profile favorable to the immune system, whereas hedonistic people, while claiming to be happy, had negative expression profiles.
First approval in sight for Novartis' CAR-T therapy after panel vote
- C. Sheridan
- MedicineNature Biotechnology
- 8 August 2017
The US, which has lagged behind Europe in approving both gene therapy and cell therapy, has now taken a lead in adopting an innovative immuno-oncology treatment that combines elements of each modality—and which addresses a real and sizeable unmet need.
Illumina claims $1,000 genome win
- C. Sheridan
- BiologyNature Biotechnology
- 7 February 2014
Drug developers are mounting a poly(ADPribose) polymerase (PARP) inhibitor comeback, and a few are now experimenting with a more comprehensive companion diagnostic to smooth the way, with more imminent competition to Imbruvica likely to come from newer, targeted agents in late-stage development, especially in CLL.
J&J's billion dollar punt on anti-amyloid antibody
- C. Sheridan
- BiologyNature Biotechnology
- 1 August 2009
A negative result would be a significant setback for the field, after the recent failures of two other anti-amyloid drugs, the gamma secretase inhibitor Flurizan and Alzhemed, which were designed to prevent beta amyloid aggregation.
First COVID-19 DNA vaccine approved, others in hot pursuit.
- C. Sheridan
- MathematicsNature Biotechnology
- 16 November 2021
Amgen's angiopoietin blocker fails in ovarian cancer
- C. Sheridan
- BiologyNature Biotechnology
- 9 January 2015
Although trebananib has definite biological effects, a precise understanding of its mechanism remains elusive, which may have led to its deployment in settings in which its performance was suboptimal, and could have a chilling effect on some drug developers investing in similar molecules.
Europe lags, US leads 2nd-generation biofuels
- C. Sheridan
- EngineeringNature Biotechnology
- 1 December 2008
...
...